Pfizer Might Have Takers for Struggling Hospira

May 5, 2016

Pfizer reportedly has several bids for its struggling Hospira business, acquired in February of last year, says Bloomberg sources.

News broke in January that Pfizer might be considering a sale, with analysts speculating that selling the devices business would leave Pfizer a more pure-play drugs unit for a possible spinoff.

According to Bloomberg, British engineering firm Smiths Group and German healthcare company Fresenius are among the current bidders. Private equity firm Pamplona Capital Management also made a second-round bid.

Sources say final bids are due by the end of May, for a deal that could be worth about $2 billion.

Read the Bloomberg coverage